Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

New England Journal of Medicine

Volumn 347, Issue 7, 2002, Pages 472-480

  Demetri, George D ^a   Von Mehren, Margaret ^b   Blanke, Charles D ^c   Van Den Abbeele, Annick D ^a   Eisenberg, Burton ^b   Roberts, Peter J ^d   Heinrich, Michael C ^c   Tuveson, David A ^a   Singer, Samuel ^a   Janicek, Milos ^a   Fletcher, Jonathan A ^a   Silverman, Stuart G ^a   Silberman, Sandra L ^e   Capdeville, Renaud ^e   Kiese, Beate ^e   Peng, Bin ^e   Dimitrijevic, Sasa ^e   Druker, Brian J ^c   Corless, Christopher ^c   Fletcher, Christopher D M ^a   Joensuu, Heikki ^f   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF TURKU   (Finland)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ABDOMINAL BLEEDING; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TUMOR; HUMAN; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; REMISSION INDUCTION; SIGNAL TRANSDUCTION; STROMAL CELLS; SURVIVAL ANALYSIS;

EID: 0037103424     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa020461     Document Type: Article

References (24)

1. Gastrointestinal stromal tumors: Recent advances in understanding of their biology
2. Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors
3. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
4. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
5. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival
6. Clinical and pathological characteristics of gastrointestinal stromal tumors (GIST)
7. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
8. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
9. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
10. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571
11. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
12. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
13. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications
14. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
15. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
16. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution
17. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry
18. Diagnosis of gastrointestinal stromal tumors: A consensus approach
19. Clinical investigation of the pharmacokinetic/pharmacodynamic relationship for Glivec (STI571): A novel inhibitor of signal transduction
20. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal tumors: A phase I study
21. Induction of resistance to Abelson inhibitor STI571 in human leukemic cells through gene amplification
22. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
23. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: A clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases